Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Clinical Translation of Stem Cells 2014

Richard Enmon's Biography

Richard Enmon, US and EU Registered Patent Attorney, Vossius and Partner

Dr. Richard Enmon’s scientific background is in biomedical engineering and molecular biology, with a focus on cancer progression. He obtained a PhD at Tulane University in New Orleans, Louisiana, in 2000, followed by post-doctoral research at Memorial Sloan-Kettering Cancer Center in New York, New York. Dr. Enmon transitioned to intellectual property law, working as a scientific advisor in two respected New York law firms, concurrently earning a J.D. from Fordham University School of Law in 2008. Dr. Enmon has been registered before the United States Patent and Trademark Office as a patent agent since 2003 and as an attorney since 2009. He has extensive experience in the drafting and prosecution of U.S. and European patent applications in the fields of molecular biology, genetics, biopharmaceuticals, small molecules and medical devices. He also has extensive experience in the preparation of validity, non-infringement, inventorship and freedom-to-operate opinions based on both U.S. and European patent law and practice. Dr. Enmon has been with the firm Vossius & Partner in Munich, Germany, since 2009 and was registered as a European Patent Attorney in 2013.

Richard Enmon Image

The Stem Cell Controversy In Intellectual Property In Europe

Tuesday, 22 April 2014 at 14:00

Add to Calendar ▼2014-04-22 14:00:002014-04-22 15:00:00Europe/LondonThe Stem Cell Controversy In Intellectual Property In EuropeClinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California,

Stem cell based technology offers unique opportunities for potentially life-changing therapies, but nevertheless remains one of the most controversial and vigorously debated fields of scientific research.  Patent rights have been developed to arguably protect and foster such scientific advancement, and, since their inception, have also explicitly rejected the protection of inventions based on unethical research, or research contrary to the ordre public.  However, recent decisions by the Technical Boards of Appeal of the European Patent Office seem to indicate that rather than interpreting the implementing provisions narrowly as proscribed, the definition of patentable subject matter is being swayed by the changing popular opinions of various member countries as reflected in their high-court decisions.  This presentation seeks to provide an overview of the changing positions taken by national and international bodies with respect to stem cell technology and its impact on the potential for future patent protections.

Add to Calendar ▼2014-04-21 00:00:002014-04-22 00:00:00Europe/LondonClinical Translation of Stem Cells 2014Clinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California,